Piramal Life Sciences Limited engages in the research, development, and commercialization of pharmaceutical products primarily in India. It develops Cyclin Dependent Kinase and PI3 Kinase inhibitors for oncology therapy; TNF production/release inhibitors and safer NSAIDs for inflammation; insulin sensitizers and DGAT1 for diabetes/metabolic disorders; and anti-infective products, such as antibacterials and antifungals for infectious diseases. The company has drug discovery and development agreements with Eli Lilly & Co., Merck & Co., and Pierre Fabre Laboratories. Piramal Life Sciences Limited is based in Mumbai, India.